PURPOSE: Antibiotics are frequently prescribed for acute nonspecific respiratory infections (ARIs), presumably to avoid small risks of progression to serious bacterial illness. However, even low risks of associated adverse drug events could result in many such events at the population level. Our objective was to assess the risks and benefits of antibiotic use in a cohort of patients with ARIs, comparing outcomes of patients who were prescribed antibiotics with outcomes of patients not receiving antibiotics. METHODS: We used a June 1986 to August 2006 cohort of adult patients with ARI visits from a UK primary care database. Exposure was an antibiotic prescribed with the visit. Primary outcomes were hospitalization within 15 days for (1) severe adverse drug events (hypersensitivity, diarrhea, seizure, arrhythmia, hepatic or renal failure), and (2) community-acquired pneumonia. RESULTS: The cohort included 1,531,019 visits with an ARI diagnosis; prescriptions for antibiotics were given in 65% of cases. The adjusted risk difference for treated vs untreated patients per 100,000 visits was 1.07 fewer adverse events (95% CI, -4.52 to 2.38; P = .54) and 8.16 fewer pneumonia hospitalizations (95% CI, -13.24 to -3.08; P = .002). The number needed to treat to prevent 1 hospitalization for pneumonia was 12,255. CONCLUSIONS: Compared with patients with ARI who were not treated with antibiotics, patients who were treated with antibiotics were not at increased risk of severe adverse drug events and had a small decreased risk of pneumonia hospitalization. This small benefit from antibiotics for a common ambulatory diagnosis creates persistent tension; at the societal level, physicians are compelled to reduce antibiotic prescribing, thus minimizing future resistance, whereas at the encounter level, they are compelled to optimize the benefit-risk balance for that patient.
PURPOSE: Antibiotics are frequently prescribed for acute nonspecific respiratory infections (ARIs), presumably to avoid small risks of progression to serious bacterial illness. However, even low risks of associated adverse drug events could result in many such events at the population level. Our objective was to assess the risks and benefits of antibiotic use in a cohort of patients with ARIs, comparing outcomes of patients who were prescribed antibiotics with outcomes of patients not receiving antibiotics. METHODS: We used a June 1986 to August 2006 cohort of adult patients with ARI visits from a UK primary care database. Exposure was an antibiotic prescribed with the visit. Primary outcomes were hospitalization within 15 days for (1) severe adverse drug events (hypersensitivity, diarrhea, seizure, arrhythmia, hepatic or renal failure), and (2) community-acquired pneumonia. RESULTS: The cohort included 1,531,019 visits with an ARI diagnosis; prescriptions for antibiotics were given in 65% of cases. The adjusted risk difference for treated vs untreated patients per 100,000 visits was 1.07 fewer adverse events (95% CI, -4.52 to 2.38; P = .54) and 8.16 fewer pneumonia hospitalizations (95% CI, -13.24 to -3.08; P = .002). The number needed to treat to prevent 1 hospitalization for pneumonia was 12,255. CONCLUSIONS: Compared with patients with ARI who were not treated with antibiotics, patients who were treated with antibiotics were not at increased risk of severe adverse drug events and had a small decreased risk of pneumonia hospitalization. This small benefit from antibiotics for a common ambulatory diagnosis creates persistent tension; at the societal level, physicians are compelled to reduce antibiotic prescribing, thus minimizing future resistance, whereas at the encounter level, they are compelled to optimize the benefit-risk balance for that patient.
Authors: Tejal K Gandhi; Saul N Weingart; Joshua Borus; Andrew C Seger; Josh Peterson; Elisabeth Burdick; Diane L Seger; Kirstin Shu; Frank Federico; Lucian L Leape; David W Bates Journal: N Engl J Med Date: 2003-04-17 Impact factor: 91.245
Authors: David Zeltser; Dan Justo; Amir Halkin; Vitaly Prokhorov; Karin Heller; Sami Viskin Journal: Medicine (Baltimore) Date: 2003-07 Impact factor: 1.889
Authors: Heiner C Bucher; Peter Tschudi; James Young; Pierre Périat; Antje Welge-Lüussen; Hansjörg Züst; Christian Schindler Journal: Arch Intern Med Date: 2003 Aug 11-25
Authors: Jonathan A Finkelstein; Christopher Stille; James Nordin; Robert Davis; Marsha A Raebel; Douglas Roblin; Alan S Go; David Smith; Christine C Johnson; Kenneth Kleinman; K Arnold Chan; Richard Platt Journal: Pediatrics Date: 2003-09 Impact factor: 7.124
Authors: Sebastian Schneeweiss; Philip S Wang; Jerry Avorn; Malcolm Maclure; Raia Levin; Robert J Glynn Journal: J Gen Intern Med Date: 2004-05 Impact factor: 6.473
Authors: Peter P Moschovis; Esther M Sampayo; Anna Cook; Gheorghe Doros; Blair A Parry; Jesiel Lombay; T Bernard Kinane; Kay Taylor; Tony Keating; Udantha Abeyratne; Paul Porter; John Carl Journal: Contemp Clin Trials Date: 2021-01-12 Impact factor: 2.226
Authors: Darius Shaw Teng Pan; Joyce Huixin Huang; Magdalene Hui Min Lee; Yue Yu; Mark I-Cheng Chen; Ee Hui Goh; Lili Jiang; Joash Wen Chen Chong; Yee Sin Leo; Tau Hong Lee; Chia Siong Wong; Victor Weng Keong Loh; Adrian Zhongxian Poh; Tat Yean Tham; Wei Mon Wong; Fong Seng Lim Journal: BMC Fam Pract Date: 2016-11-03 Impact factor: 2.497
Authors: Magdalene Hui Min Lee; Darius Shaw Teng Pan; Joyce Huixin Huang; Mark I-Cheng Chen; Joash Wen Chen Chong; Ee Hui Goh; Lili Jiang; Yee Sin Leo; Tau Hong Lee; Chia Siong Wong; Victor Weng Keong Loh; Fong Seng Lim; Adrian Zhongxian Poh; Tat Yean Tham; Wei Mon Wong; Yue Yu Journal: Antimicrob Agents Chemother Date: 2017-04-24 Impact factor: 5.191
Authors: Xue Han; Ding-Kun Zhang; Fang Zhang; Jun-Zhi Lin; Hong Jiang; Yang Lan; Xi Xiong; Li Han; Ming Yang; Chao-Mei Fu Journal: Pharmacogn Mag Date: 2017-07-19 Impact factor: 1.085